Hypopigmentary Skin Disorders: Current Treatment Options and Future Directions

Drugs

Volumn 64, Issue 1, 2004, Pages 89-107

  Hartmann, Anke ^a   Bröcker, Eva B ^a   Becker, Jürgen C ^a,b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERMEDIN; ANTIINFLAMMATORY AGENT; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CATALASE; CLOBETASOL; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; KHELLIN; LEVAMISOLE; MELANOTAN; METHOXSALEN; MONOPHENOL MONOOXYGENASE; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; PHOTOSENSITIZING AGENT; PIMECROLIMUS; PREDNISOLONE; SUPLATAST TOSYLATE; TACROLIMUS; TRIAMCINOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XENON;

ACNE; ADVERSE DRUG REACTION; ALBINISM; AUTOIMMUNE DISEASE; AUTOTRANSPLANTATION; BLISTER; CELLULAR IMMUNITY; CLINICAL TRIAL; CONGENITAL DISORDER; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ECCHYMOSIS; ENZYME ACTIVITY; EXCIMER LASER; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMORAL IMMUNITY; HYPERPIGMENTATION; HYPERTENSION; HYPERTRICHOSIS; HYPOPIGMENTATION; IMMUNOMODULATION; INSOMNIA; KIDNEY DISEASE; LEUKODERMA; LIVER FUNCTION TEST; MELANOCYTE; MELANOMA; MENSTRUATION DISORDER; NAUSEA; PALLIATIVE THERAPY; PATHOGENESIS; PHENYLKETONURIA; PHOTOTHERAPY; PHOTOTOXICITY; PIEBALDISM; PSORIASIS; PUVA; RADIATION DOSE; RELAPSE; REVIEW; ROSACEA; SKIN ATROPHY; SKIN TRANSPLANTATION; STRIA; TELANGIECTASIA; TH2 CELL; TISSUE ENGINEERING; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VIRAL GENE THERAPY; VITILIGO; WEIGHT GAIN;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS; GENE THERAPY; HUMANS; HYPOPIGMENTATION; PHOTOTHERAPY; PIEBALDISM; VITILIGO;

ROSACEA;

EID: 1642451800     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464010-00006     Document Type: Review

References (170)

1. Boissy RE, Nordlund JJ. Molecular basis of congenital hypopigmentary disorders in humans. Pigment Cell Res 1997; 10 (1-2): 12-24
2. Nordlund JJ, Abdel-Malek ZA, Boissy RE, et al. Pigment cell biology: an historical review. J Invest Dermatol 1989; 92: 53S-60S
3. Lerner AB, Case JD. Pigment cell regulatory factors. J Invest Dermatol 1959; 32: 211
4. Jimbow K, Quevedo Jr WC, Fitzpatrick TB, et al. Some aspects of melanin biology: 1950-1975. J Invest Dermatol 1976; 67 (1): 72-89
5. Bolognia JL, Pawelek JM. Biology of hypopigmentation. J Am Acad Dermatol 1988; 19: 217-55
6. King RA, Oetting WS. Disorders of melanocytes. In: Fitzpatrick TB, Freedberg IM, Eisen AZ, et al., editors. Dermatology in general medicine. New York (NY): McGraw-Hill Inc, 1999: 925-936
7. Naughton GK, Reggiardo D, Bystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986; 15: 978-81
8. Becker JC, Guldberg P, Zeuthen J, et al. Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol 1999; 113 (6): 1033-8
9. Van den Wijngaard R, Wankowicz-Kalinska A, Pals S, et al. Autoimmune melanocyte destruction in vitiligo. Lab Invest 2001; 81: 1061-7
10. Huang CL, Nordlund JJ, Boissy R. Vitiligo: a manifestation of apoptosis? Am J Clin Dermatol 2002; 3: 301-8
11. Moretti S, Spallanzani A, Amato L, et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002; 15: 87-92
12. Mosher DB, Fitzpatrick TB, Ortonne JP, et al. Disorders of pigmentation. In: Fitzpatrick TB, Freedberg IM, editors. Fitzpatrick's dermatology in general medicine. 5th ed. New York: McGraw-Hill, Health Professions Division, 1999: 945-55
13. Cui J, Shen LY, Wang GC. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol 1991; 97 (3): 410-6
14. Cui J, Arita Y, Bystryn JC. Cytolytic antibodies to melanocytes in vitiligo. J Invest Dermatol 1993; 100 (6): 812-5
15. Pedersen LO, Vetter CS, Mingari MC, et al. Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma: a case report. J Invest Dermatol 2002; 118 (4): 595-9
16. Liu PY, Bondesson L, Lontz W, et al. The occurrence of cutaneous nerve endings and neuropeptides in vitiligo vulgaris: a case-control study. Arch Dermatol Res 1996; 288 (11): 670-5
17. Grimes PE, Sevall JS, Vojdani A. Cytomegalovirus DNA identified in skin biopsy specimens of patients with vitiligo. J Am Acad Dermatol 1996; 35 (1): 21-6
18. Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991; 97 (6): 1081-5
19. Schallreuter KU, Wood JM, Pittelkow MR, et al. Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin. Science 1994; 263 (5152): 1444-6
20. Ziegler I, Schott K, Lubbert M, et al. Control of tetrahydrobiopterin synthesis in T lymphocytes by synergistic action of interferon-gamma and interleukin-2. J Biol Chem 1990; 265 (28): 17026-30
21. Lassus A, Halme K, Eskelinen A, et al. Treatment of vitiligo with oral methoxsalen and UVA. Photodermatol 1984; 1 (4): 170-3
22. Grimes PE. Psoralen photochemotherapy for vitiligo. Clin Dermatol 1997; 15 (6): 921-6
23. Wildfang IL, Jacobsen FK, Thestrup-Pedersen K. PUVA treatment of vitiligo: a retrospective study of 59 patients. Acta Derm Venereol 1992; 72 (4): 305-6
24. Kwok YK, Anstey AV, Hawk JL. Psoralen photochemotherapy (PUVA) is only moderately effective in widespread vitiligo: a 10-year retrospective study. Clin Exp Dermatol 2002; 27 (2): 104-10
25. Westerhof W, Nieuweboer-Krobotova L, Mulder PG, et al. Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol 1999; 135 (9): 1061-6
26. Grimes PE, Minus HR, Chakrabarti SG, et al. Determination of optimal topical photochemotherapy for vitiligo. J Am Acad Dermatol 1982; 7 (6): 771-8
27. Kreuter A, Gambichler T, Avermaete A, et al. Localized vitiligo successfully treated with cream-psoralen + ultraviolet A. J Eur Acad Dermatol Venereol 2001; 15 (4): 357-8
28. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for vitiligo: American Academy of Dermatology. J Am Acad Dermatol 1996; 35 (4): 620-6
29. Ortel B, Tanew A, Honigsmann H. Treatment of vitiligo with khellin and ultraviolet A. J Am Acad Dermatol 1988; 18: 693-701
30. Orecchia G, Perfetti L. Photochemotherapy with topical khellin and sunlight in vitiligo. Dermatology 1992; 184 (2): 120-3
31. Cormane RH, Siddiqui AH, Westerhof W, et al. Phenylalanine and UVA light for the treatment of vitiligo. Arch Dermatol Res 1985; 277 (2): 126-30
32. Siddiqui AH, Stolk LM, Bhaggoe R, et al. L-phenylalanine and UVA irradiation in the treatment of vitiligo. Dermatology 1994; 188 (3): 215-8
33. Rosenbach T, Wellenreuther U, Nurnberger F, et al. Treatment of vitiligo with phenylalanine and UV-A. Hautarzt 1993; 44 (4): 208-9
34. Njoo MD, Spuls PI, Bos JD, et al. Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature. Arch Dermatol 1998; 134 (12): 1532-40
35. Köster W, Wiskemann A. Phototherapy with UV-B in vitiligo. Z Hautkr 1990; 65 (11): 1022-4, 1029
36. Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol 1997; 133 (12): 1525-8
37. Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol 2001; 44 (6): 999-1003
38. Mofty ME, Zaher H, Esmat S, et al. PUVA and PUVB in vitiligo: are they equally effective? Photodermatol Photoimmunol Photomed 2001; 17 (4): 159-63
39. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000; 42: 245-53
40. 311nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol. In press
41. Slaper H, Schothorst AA, van der Leun JC. Risk evaluation of UVB therapy for psoriasis: comparison of calculated risk for UVB therapy and observed risk in PUVA-treated patients. Photodermatol 1986; 3 (5): 271-83
42. Schallreuter KU, Wood JM, Lemke KR, et al. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology 1995; 190 (3): 223-9
43. Schallreuter KU. Pseudocatalase in the treatment of vitiligo. In: Hann SK, Nordlund J, editors. Vitiligo: a monograph on the basic and clinical science. Pt 4. Berlin: Blackwell Science Inc., 2000
44. Kokelj F, Lavaroni G, Perkan V, et al. Hyperpigmentation due to calcipotriol (MC 903) plus heliotherapy in psoriatic patients: three case reports. Acta Derm Venereol 1995; 75 (4): 307-9
45. Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology 1998; 197 (2): 167-70
46. Parsad D, Saini R, Nagpal R. Calcipotriol in vitiligo: a preliminary study. Pediatr Dermatol 1999; 16 (4): 317-20
47. Yalcin B, Sahin S, Bukulmez G, et al. Experience with calcipotriol as adjunctive treatment for vitiligo in patients who do not respond to PUVA alone: a preliminary study. J Am Acad Dermatol 2001; 44 (4): 634-7
48. Ermis O, Alpsoy E, Cetin L, et al. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol?: a placebo-controlled double-blind study. Br J Dermatol 2001; 145 (3): 472-5
49. Chiaverini C, Passeron T, Ortonne JP. Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol 2002; 16 (2): 137-8
50. Hanada K, Sawamura D, Nakano H, et al. Possible role of 1,25-dihydroxyvitamin D3-induced metallothionein in photoprotection against UVB injury in mouse skin and cultured rat keratinocytes. J Dermatol Sci 1995; 9: 203-8
51. McKenna KE, Stern RS. Photosensitivity associated with combined UV-B and calcipotriene therapy. Arch Dermatol 1995; 131 (11): 1305-7
52. Youn JI, Park BS, Chung JH, et al. Photoprotective effect of calcipotriol upon skin photoreaction to UVA and UVB. Photodermatol Photoimmunol Photomed 1997; 13 (3): 109-14
53. Bonis B, Kemeny L, Dobozy A, et al. 308 nm UVB excimer laser for psoriasis [letter]. Lancet 1997; 350 (9090): 1522
54. Baltas E, Nagy P, Bonis B, et al. Repigmentation of localized vitiligo with the xenon chloride laser. Br J Dermatol 2001; 144 (6): 1266-7
55. Friedman PM, Geronemus RG. Use of the 308-nm excimer laser for postresurfacing leukoderma. Arch Dermatol 2001; 137 (6): 824-5
56. Spencer JM, Nossa R, Ajmeri J. Treatment of vitiligo with the 308-nm excimer laser: a pilot study. J Am Acad Dermatol 2002; 46 (5): 727-31
57. Anderson RR, Parrish JA. The optics of human skin. J Invest Dermatol 1981; 77 (1): 13-9
58. Green H, Boll J, Parrish JA, et al. Cytotoxicity and mutagenicity of low intensity, 248 and 193 nm excimer laser radiation in mammalian cells. Cancer Res 1987 Jan 15; 47 (2): 410-3
59. Kochevar IE. Cytotoxicity and mutagenicity of excimer laser radiation. Lasers Surg Med 1989; 9 (5): 440-5
60. Scheibenbogen C, Hunstein W, Keilholz U. Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. Eur J Cancer 1994; 30A (8): 1209-11
61. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18: 175-82
62. Le Poole IC, van den Wijngaard RM, Westerhof W, et al. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996; 148: 1219-28
63. Badri AM, Todd PM, Garioch JJ, et al. An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol 1993; 170 (2): 149-55
64. Abdel-Naser MB, Hann SK, Bystryn JC. Oral psoralen with UV-A therapy releases circulating growth factor (s) that stimulates cell proliferation. Arch Dermatol 1997; 133 (12): 1530-3
65. Gonzalo JA, Gonzalez-Garcia A, Martinez C, et al. Glucocorticoid- mediated control of the activation and clonal deletion of peripheral T cells in vivo. J Exp Med 1993; 177 (5): 1239-46
66. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function*. Annu Rev Immunol 2000; 18: 309-45
67. Hann SK, Kim HI, Im S, et al. The change of melanocyte cytotoxicity after systemic steroid treatment in vitiligo patients. J Dermatol Sci 1993 Dec; 6 (3): 201-5
68. Uda H, Takei M, Mishima Y. Immunopathology of vitiligo vulgaris, Sutton's leukoderma and melanoma-associated vitiligo in relation to steroid effects: II. the IgG and C3 deposits in the skin. J Cutan Pathol 1984; 11 (2): 114-24
69. Becker JC, Varki NM, Bröcker EB, et al. Lymphocyte-mediated alopecia in C57BL6 mice following successful immunotherapy for melanoma. J Invest Dermatol 1996; 107: 627-32
70. Miyaura H, Iwata M. Direct and indirect inhibition of Th1 development by progesterone and glucocorticoids. J Immunol 2002; 168 (3): 1087-94
71. Bleehen SS. The treatment of vitiligo with topical corticosteroids. Light and electronmicroscopic studies. Br J Dermatol 1976 Mar; 94 Suppl. 12: 43-50
72. Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol 1984; 120 (5): 631-5
73. Liu XQ, Shao CG, Jin PY, et al. Treatment of localized vitiligo with ulobetasol cream. Int J Dermatol 1990; 29 (4): 295-7
74. Goldstein E, Haberman HF, Menon IA, et al. Non-psoralen treatment of vitiligo. Part I: cosmetics, systemic coloring agents, and corticosteroids. Int J Dermatol 1992; 31 (4): 229-36
75. Cockayne SE, Messenger AG, Gawkrodger DJ. Vitiligo treated with topical corticosteroids: children with head and neck involvement respond well. J Am Acad Dermatol 2002; 46 (6): 964-5
76. Nielsen NV, Sorensen PN. Glaucoma induced by application of corticosteroids to the periorbital region. Arch Dermatol 1978; 114 (6): 953-4
77. Kandil E. Treatment of vitiligo with 0-1 per cent betamethasone 17-valerate in isopropyl alcohol: a double-blind trial. Br J Dermatol 1974; 91 (4): 457-60
78. Imamura S, Tagami H. Treatment of vitiligo with oral corticosteroids. Dermatologica 1976; 153 (3): 179-85
79. Kim SM, Lee HS, Hann SK. The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients. Int J Dermatol 1999; 38 (7): 546-50
80. Radakovic-Fijan S, Furnsinn-Friedl AM, Honigsmann H, et al. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol 2001; 44 (5): 814-7
81. Pasricha JS, Khaitan BK. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol 1993; 32 (10): 753-7
82. Kanwar AJ, Dhar S, Dawn G. Oral minipulse therapy in vitiligo. Dermatology 1995; 190 (3): 251-2
83. Seiter S, Ugurel S, Tilgen W, et al. Use of high-dose methylprednisolone pulse therapy in patients with progressive and stable vitiligo. Int J Dermatol 2000 Aug; 39 (8): 624-7
84. Cather JC, Abramovits W, Menter A. Cyclosporine and tacrolimus in dermatology. Dermatol Clin 2001 Jan; 19 (1): 119-37
85. Gupta AK, Ellis CN, Nickoloff BJ, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses: a clinical and immunopathologic analysis. Arch Dermatol 1990 Mar; 126 (3): 339-50
86. Szeto C, Gillespie KM, Mathieson PW. Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance. Immunology 2000 Jun; 100 (2): 217-24
87. Loutfi A, Shakr A, Jerry M, et al. Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. Clin Invest Med 1987; 10 (4): 325-8
88. Pasricha JS, Khera V. Effect of prolonged treatment with levamisole on vitiligo with limited and slow-spreading disease. Int J Dermatol 1994; 33 (8): 584-7
89. Oda N, Minoguchi K, Yokoe T, et al. Effect of suplatast tosilate (IPD-1151T) on cytokine production by allergen-specific human Th1 and Th2 cell lines. Life Sci 1999; 65 (8): 763-70
90. Nihei Y, Nishibu A, Kaneko F. Suplatast tosilate (IPD), a new immunoregulator, is effective in vitiligo treatment. J Dermatol 1998; 25 (4): 250-5
91. Tamaoki J, Kondo M, Sakai N, et al. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study: Tokyo Joshi-Idai Asthma Research Group. Lancet 2000; 356 (9226): 273-8
92. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002; 62 (5): 817-40
93. Gupta AK, Adamiak A, Chow M. Tacrolimus: a review of its use for the management of dermatoses. J Eur Acad Dermatol Venereol 2002; 16 (2): 100-14
94. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 10: 1-3
95. Smith DA, Tofte SJ, Hanifin JM. Repigmentation of vitiligo with topical tacrolimus. Dermatology 2002; 205: 301-3
96. Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-5
97. Thody AJ. Alpha-MSH and the regulation of melanocyte function. Ann N Y Acad Sci 1999 Oct 20; 885: 217-29
98. Graham A, Westerhof W, Thody AJ. The expression of alpha-MSH by melanocytes is reduced in vitiligo. Ann N Y Acad Sci 1999; 885: 470-3
99. Ugwu SO, Blanchard J, Dorr RT, et al. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos 1997 Apr; 18 (3): 259-69
100. Dorr RT, Dvorakova K, Brooks C, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [N1e4-D-Phe7]-alpha-MSH in humans. Photochem Photobiol 2000; 72 (4): 526-32
101. Lerner AB, Snell RS, Chanco-Tumer ML, et al. Vitiligo and sympathectomy: the effect of sympathectomy and a-melanocyte stimulating hormone. Arch Dermatol 1966; 94: 269-78
102. Muto M, Furumoto H, Ohmura A, et al. Successful treatment of vitiligo with a sex steroid-thyroid hormone mixture. J Dermatol 1995; 22: 770-2
103. Ichimiya M. Immunohistochemical study of ACTH and alpha-MSH in vitiligo patients successfully treated with a sex steroid-thyroid hormone mixture. J Dermatol 1999; 26: 502-6
104. Westerhof W, Boersma B. The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation. J Am Acad Dermatol 1995; 33 (6): 1061-2
105. Falabella R, Arrunategui A, Barona MI, et al. The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation. J Am Acad Dermatol 1995; 32 (2 Pt 1): 228-32
106. Mutalik S, Ginzburg A. Surgical management of stable vitiligo: a review with personal experience. Dermatol Surg 2000 Mar; 26 (3); 248-54
107. Sachdev M, Shankar DS. Dermatologie surgery: pulsed erbium: YAG laser-assisted autologous epidermal punch grafting in vitiligo. Int J Dermatol 2000; 39 (11): 868-71
108. Malakar S, Dhar S. Treatment of stable and recalcitrant vitiligo by autologous miniature punch grafting: a prospective study of 1000 patients. Dermatology 1999; 198 (2): 133-9
109. Boersma BR, Westerhof W, Bos JD. Repigmentation in vitiligo vulgaris by autologous minigrafting: results in nineteen patients. J Am Acad Dermatol 1995; 33 (6): 990-5
110. Falabella R. Treatment of localized vitiligo by autologous minigrafting. Arch Dermatol 1988 Nov; 124 (11): 1649-55
111. Njoo MD, Westerhof W, Bos JD, et al. A systematic review of autologous transplantation methods in vitiligo. Arch Dermatol 1998 Dec; 134 (12): 1543-9
112. Falabella R, Barona M, Escobar C, et al. Surgical combination therapy for vitiligo and piebaldism. Dermatol Surg 1995 Oct; 21 (10): 852-7
113. Falabella R. Epidermal grafting: an original technique and its application in achromic and granulating areas. Arch Dermatol 1971; 107: 592-600
114. Hann SK, Im S, Bong HW, et al. Treatment of stable vitiligo with autologous epidermal grafting and PUVA. J Am Acad Dermatol 1995 Jun; 32 (6): 943-8
115. Kim HY, Kang KY. Epidermal grafts for treatment of stable and progressive vitiligo. J Am Acad Dermatol 1999 Mar; 40 (3): 412-7
116. Yang JS, Kye YC. Treatment of vitiligo with autologous epidermal grafting by means of pulsed erbium: YAG laser. J Am Acad Dermatol 1998 Feb; 38 (2 Pt 1): 280-2
117. Oh CK, Cha JH, Lim JY, et al. Treatment of vitiligo with suction epidermal grafting by the use of an ultrapulse CO2 laser with a computerized pattern generator. Dermatol Surg 2001 Jun; 27 (6): 565-8
118. Olsson MJ, Juhlin L. Epidermal sheet grafts for repigmentation of vitiligo and piebaldism, with a review of surgical techniques. Acta Derm Venereol 1997 Nov; 77 (6): 463-6
119. Kahn AM, Cohen MJ. Repigmentation in vitiligo patients. Melanocyte transfer via ultra-thin grafts. Dermatol Surg 1998 Mar; 24 (3): 365-7
120. Njoo MD, Nieuweboer-Krobotova L, Westerhof W. Repigmentation of leucodermic defects in piebaldism by dermabrasion and thin split-thickness skin grafting in combination with minigrafting. Br J Dermatol 1998 Nov; 139 (5): 829-33
121. Ozdemir M, Cetinkale O, Wolf R, et al. Comparison of two surgical approaches for treating vitiligo: a preliminary study. Int J Dermatol 2002 Mar; 41 (3): 135-8
122. Olsson MJ, Moellmann G, Lerner AB, et al. Vitiligo: repigmentation with cultured melanocytes after cryostorage. Acta Derm Venereol 1994; 74 (3): 226-8
123. Zachariae H, Zachariae C, Deleuran B, et al. Autotransplantation in vitiligo: treatment with epidermal grafts and cultured melanocytes. Acta Derm Venereol 1993 Feb; 73 (1): 46-8
124. Lontz W, Olsson MJ, Moellmann G, et al. Pigment cell transplantation for treatment of vitiligo: a progress report. J Am Acad Dermatol 1994; 30 (4): 591-7
125. Olsson MJ, Juhlin L. Transplantation of melanocytes in vitiligo. Br J Dermatol 1995; 132 (4): 587-91
126. Kaufmann R, Greiner D, Kippenberger S, et al. Grafting of in vitro cultured melanocytes onto laser-ablated lesions in vitiligo. Acta Derm Venereol 1998; 78 (2): 136-8
127. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975; 6 (3): 331-43
128. Falabella R, Escobar C, Borrero I. Treatment of refractory and stable vitiligo by transplantation of in vitro cultured epidermal autografts bearing melanocytes. J Am Acad Dermatol 1992; 26 (2 Pt 1): 230-6
129. Andreassi L, Pianigiani E, Andreassi A, et al. A new model of epidermal culture for the surgical treatment of vitiligo. Int J Dermatol 1998; 37 (8): 595-8
130. Guerra L, Capurro S, Melchi F, et al. Treatment of "stable" vitiligo by Timedsurgery and transplantation of cultured epidermal autografts. Arch Dermatol 2000; 136 (11): 1380-9
131. Horch RE. Tissue engineering and the skin: development of cultured skin substitutes from sheets and composites to suspensions and monolayers on biological carrier materials. In: Horch RE, Munster AM, Achauer BM, editors. Cultured human keratinocytes and tissue engineered skin substitutes. Stuttgart: Georg Thieme, 2001: 3-22
132. Bessou S, Surleve-Bazeille JE, Sorbier E, et al. Ex vivo reconstruction of the epidermis with melanocytes and the influence of UVB. Pigment Cell Res 1995 Oct; 8 (5): 241-9
133. Regnier M, Staquet MJ, Schmitt D, et al. Integration of Langerhans cells into a pigmented reconstructed human epidermis. J Invest Dermatol 1997; 109 (4): 510-2
134. Lerner AB, Halaban R, Klaus SN, et al. Transplantation of human melanocytes. J Invest Dermatol 1987; 89 (3): 219-24
135. Olsson MJ, Juhlin L. Melanocyte transplantation in vitiligo [letter]. Lancet 1992 Oct 17; 340 (8825): 981
136. Olsson MJ, Juhlin L. Repigmentation of vitiligo by transplantation of cultured autologous melanocytes. Acta Derm Venereol 1993; 73 (1): 49-51
137. Hayashibe K, Mishima Y. Tyrosinase-positive melanocyte distribution and induction of pigmentation in human piebald skin. Arch Dermatol 1988; 124 (3): 381-6
138. Giebel LB, Spritz RA. Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Proc Natl Acad Sci U S A 1991 Oct 1; 88 (19): 8696-9
139. Spitz RA. Molecular basis of human piebaldism. J Invest Dermatol 1994; 103: 137-140S
140. Nishikawa S, Kusakabe M, Yoshinaga K, et al. In utero manipulation of coat color formation by a monoclonal anti-c-kit antibody: two distinct waves of c-kit-dependency during melanocyte development. EMBO J 1991 Aug; 10 (8): 2111-8
141. Fukai K, Hamada T, Ishii M, et al. Acquired pigmented macules in human piebald lesions: ultrastructure of melanocytes in hypomelanotic skin. Acta Derm Venereol 1989; 69 (6): 524-7
142. Olsson MJ, Juhlin L. Leucoderma treated by transplantation of a basal cell layer enriched suspension. Br J Dermatol 1998; 138 (4): 644-8
143. Costa OG. Leucopathie symétrique progressive des extrémitées. Ann Dermatol 1951; 78: 452-4
144. Cummings KI, Cottel WI. Idiopathic guttate hypomelanosis. Arch Dermatol 1966; 93 (2): 184-6
145. Whitehead WJ, Moyer DG, Vander Ploeg DE. Idiopathic guttate hypomelanosis. Arch Dermatol 1966; 94 (3): 279-81
146. Falabella R, Escobar C, Giraldo N, et al. On the pathogenesis of idiopathic guttate hypomelanosis. J Am Acad Dermatol 1987; 16 (1 Pt 1): 35-44
147. Wilson PD, Lavker RM, Kligman AM. On the nature of idiopathic guttate hypomelanosis. Acta Derm Venereol 1982; 62 (4): 301-6
148. Ortonne JP, Perrot H. Idiopathic guttate hypomelanosis. Ultrastructural study. Arch Dermatol 1980; 116 (6): 664-8
149. Ploysangam T, Dee-Ananlap S, Suvanprakom P. Treatment of idiopathic guttate hypomelanosis with liquid nitrogen: light and electron microscopic studies. J Am Acad Dermatol 1990; 23 (4 Pt 1): 681-4
150. Wallace ML, Grichnik JM, Prieto VG, et al. Numbers and differentiation status of melanocytes in idiopathic guttate hypomelanosis. J Cutan Pathol 1998; 25 (7): 375-9
151. Suvanprakorn P, Dee-Ananlap S, Pongsomboon C, et al. Melanocyte autologous grafting for treatment of leukoderma. J Am Acad Dermatol 1985; 13 (6): 968-74
152. Ruiz-Maldonado R, Orozco-Covarrubias ML. Postinflammatory hypopigmentation and hyperpigmentation. Semin Cutan Med Surg 1997; 16 (1): 36-43
153. Iliev D, Elsner P. An unusual hypopigmentation in occupational dermatology: presentation of a case and review of the literature. Dermatology 1998; 196 (2): 248-50
154. Herlyn M, Shih IM. Interactions of melanocytes and melanoma cells with the microenvironment. Pigment Cell Res 1994; 7 (2): 81-8
155. Gordon PR, Mansur CP, Gilchrest BA. Regulation of human melanocyte growth, dendricity, and melanization by keratinocyte derived factors. J Invest Dermatol 1989; 92 (4): 565-72
156. Imokawa G, Motegi I. Skin organ culture model for examining epidermal melanization. J Invest Dermatol 1993; 100 (1): 47-54
157. Horikawa T, Norris DA, Yohn JJ, et al. Melanocyte mitogens induce both melanocyte chemokinesis and chemotaxis. J Invest Dermatol 1995; 104 (2): 256-9
158. Halaban R. The regulation of normal melanocyte proliferation. Pigment Cell Res 2000; 13 (1): 4-14
159. Moretti S, Spallanzani A, Amato L, et al. Vitiligo and epidermal microenvironment: possible involvement of keratinocyte-derived cytokines. Arch Dermatol 2002; 138 (2): 273-4
160. Greenhalgh DA, Rothnagel JA, Roop DR. Epidermis: an attractive target tissue for gene therapy. J Invest Dermatol 1994; 103 (5 Suppl.): 63S-9S
161. Bell E, Sher S, Hull B, et al. The reconstitution of living skin. J Invest Dermatol 1983; 81 (1 Suppl.): 2s-10s
162. Pellegrini G, Bondanza S, Guerra L, et al. Cultivation of human keratinocyte stem cells: current and future clinical applications. Med Biol Eng Comput 1998; 36 (6): 778-90
163. Davidson JM, Krieg T, Eming SA. Particle-mediated gene therapy of wounds. Wound Repair Regen 2000; 8 (6): 452-9
164. Lin MT, Pulkkinen L, Uitto J. Cutaneous gene therapy: principles and prospects. Dermatol Clin 2000; 18 (1): 177-88
165. Andree C, Swain WF, Page CP, et al. In vivo transfer and expression of a human epidermal growth factor gene accelerates wound repair. Proc Natl Acad Sci U S A 1994 Dec 6; 91 (25): 12188-92
166. Sun L, Xu L, Chang H, et al. Transfection with aFGF cDNA improves wound healing. J Invest Dermatol 1997; 108 (3): 313-8
167. Meuli M, Liu Y, Liggitt D, et al. Efficient gene expression in skin wound sites following local plasmid injection. J Invest Dermatol 2001; 116 (1): 131-5
168. Nagasaki Y, Matsubara Y, Takano H, et al. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. Pediatr Res 1999; 45 (4 Pt 1): 465-73
169. Gallico III GG, O'Connor NE, Compton CC, et al. Permanent coverage of large bum wounds with autologous cultured human epithelium. N Engl J Med 1984 16; 311 (7): 448-51
170. Hunyadi J, Farkas B, Bertenyi C, et al. Keratinocyte grafting: a new means of transplantation for full-thickness wounds. J Dermatol Surg Oncol 1988; 14: 75-8